Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing Dilemmas.
Document Type
Article
Publication Date
5-2023
Identifier
DOI: 10.1016/j.iac.2023.01.011
Abstract
Hypersensitivity pneumonitis (HP) is a heterogenous disease entity characterized by an aberrant immune response to inhalational antigens. Disease modification hinges on early antigen remediation with a goal to attenuate immune dysregulation. Disease severity and progression are mediated by an interface between degree, type and chronicity of exposure, genetic predisposition, and biochemical properties of the inducing agent. Guidelines have provided a standardized approach; however, decision-making remains with many clinical dilemmas. The delineation of fibrotic and nonfibrotic HP is crucial to identify the differences in clinical trajectories, and further clinical trials are needed to understand optimal therapeutic strategies.
Journal Title
Immunology and allergy clinics of North America
Volume
43
Issue
2
First Page
245
Last Page
257
MeSH Keywords
Humans; Alveolitis, Extrinsic Allergic; Antigens
Keywords
Exposure; Fibrotic; Hypersensitivity pneumonitis; Interstitial lung disease; Lymphocytosis.
Recommended Citation
Pandya SM, Pandya AP, Fels Elliott DR, Hamblin MJ. Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing Dilemmas. Immunol Allergy Clin North Am. 2023;43(2):245-257. doi:10.1016/j.iac.2023.01.011
COinS
